The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours - PubMed (original) (raw)
Review
The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours
Max S Mano et al. Cancer Treat Rev. 2007 Feb.
Abstract
Her2 and topoisomerase-IIalpha (T2A) gene amplification are separate events, although the latter is more frequently seen in Her2 amplified (34-90%) than in Her2 non-amplified (5-10%) tumours. There is a better correlation between Her2 amplification and protein overexpression in breast cancer (BC) than in other tumour types. This marker is also considered a powerful prognostic factor in BC, with similar data emerging in other solid tumours such as bladder, ovarian, endometrial, gastro-oesophageal and non-small cell lung cancer. Her2 amplification and/or overexpression are highly predictive of response to HER2-targeted compounds such as trastuzumab and lapatinib but have been inconsistent predictors of response to cytotoxic chemotherapy. There is also evidence that these tumours are relatively resistant to anti-oestrogen therapy (tamoxifen) but not to oestrogen deprivation (e.g. with aromatase inhibitors). T2A aberrations are uncommon events in solid tumours, with an overall prevalence of approximately 10%. T2A amplification has shown inconsistent correlation with T2A protein expression in preclinical and clinical studies, mainly because non-genetic events such as proliferation rate can also affect protein expression. Expression of T2A protein has not been shown to reliably predict response to T2A inhibitors, despite the fact that this enzyme is the direct target for these compounds. In BC, T2A amplification appears to be a good predictor of response to anthracyclines, but these data are still in the process of validation. The significance of T2A deletions is currently under investigation, but contrary to what was previously thought, it may also predict benefit from treatment with T2A inhibitors. The prognostic significance of T2A aberrations is currently unknown.
Similar articles
- Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M. Mano MS, et al. Gynecol Oncol. 2004 Mar;92(3):887-95. doi: 10.1016/j.ygyno.2003.12.010. Gynecol Oncol. 2004. PMID: 14984957 - Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Orlando L, et al. Breast. 2008 Oct;17(5):506-11. doi: 10.1016/j.breast.2008.03.007. Epub 2008 May 5. Breast. 2008. PMID: 18456496 - TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C. Villman K, et al. Acta Oncol. 2006;45(5):590-6. doi: 10.1080/02841860500543182. Acta Oncol. 2006. PMID: 16864174 - New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
Gennari A, Pronzato P. Gennari A, et al. Clin Breast Cancer. 2008 Dec;8 Suppl 4:S179-83. doi: 10.3816/CBC.2008.s.015. Clin Breast Cancer. 2008. PMID: 19158039 Review. - HER-2 and topoisomerase II as predictors of response to chemotherapy.
Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. Pritchard KI, et al. J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716. J Clin Oncol. 2008. PMID: 18258981 Review.
Cited by
- The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH, Yu J, Huang MY, Mo YM. Ye JH, et al. Breast Cancer. 2024 May;31(3):417-425. doi: 10.1007/s12282-024-01553-x. Epub 2024 Apr 1. Breast Cancer. 2024. PMID: 38561479 Free PMC article. - Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Dai LJ, Ma D, Xu YZ, Li M, Li YW, Xiao Y, Jin X, Wu SY, Zhao YX, Wang H, Yang WT, Jiang YZ, Shao ZM. Dai LJ, et al. Nat Commun. 2023 Aug 22;14(1):5112. doi: 10.1038/s41467-023-40715-x. Nat Commun. 2023. PMID: 37607916 Free PMC article. - Identification of key protein-coding genes in lung adenocarcinomas based on bioinformatic analysis.
Yao R, Chen X, Wang L, Wang Y, Chi S, Li N, Tian X, Li N, Liu J. Yao R, et al. Transl Cancer Res. 2019 Dec;8(8):2829-2840. doi: 10.21037/tcr.2019.10.45. Transl Cancer Res. 2019. PMID: 35117040 Free PMC article. - Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions.
Andersson A, Larsson L, Stenbeck L, Salmén F, Ehinger A, Wu SZ, Al-Eryani G, Roden D, Swarbrick A, Borg Å, Frisén J, Engblom C, Lundeberg J. Andersson A, et al. Nat Commun. 2021 Oct 14;12(1):6012. doi: 10.1038/s41467-021-26271-2. Nat Commun. 2021. PMID: 34650042 Free PMC article. - Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy.
Soave A, Kluwe L, Yu H, Rink M, Gild P, Vetterlein MW, Marks P, Sauter G, Fisch M, Meyer CP, Ludwig T, Dahlem R, Minner S, Pantel K, Steinbach B, Schwarzenbach H. Soave A, et al. Sci Rep. 2020 Dec 9;10(1):21562. doi: 10.1038/s41598-020-75869-x. Sci Rep. 2020. PMID: 33298978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous